Amorepacific Corporation

Jihae Lee

Byoung Young Woo

Miyoung Park

Wonkyung Cho

Jong Hwa Roh

Kyoungmi Jung

Chang Soon Choi

Jaehong Park

Youngho Park

Kwanghyun Shin

Joonho Choi

Eunsil Park

Gyeyoung Choi

Kiwha Lee

Hyunjin Nam

Young-Ho Park

Chan Woong Park

Ki-Wha Lee

Su Hwan Kim

Wanki Kim

Changyong Moon

Sarva Jayaprakash

Sridhar Regati

Mamidi Srinivas

Krushnakant Patel

M Ramamohan

The present disclosure relates to a composition for improving sleep quality, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof. The composition for improving sleep quality may improve the sleep quality by increasing melatonin secretion. In addition, in another aspect, the present disclosure provides a composition for alleviating stress, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof.

GABA complex composition

Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.

Composition for preventing or treating atopic dermatitis

Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)&#x2014;N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.

Composition for preventing or treating sleep disorders

Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliaries and the recrystallization and separation of optical isomers. According to the above method, high-purity N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide with excellent quality can be produced at room temperature by improving cryogenic process conditions necessary for realizing high optical purity, and thus the trimming due to the process failure rate can be remarkably reduced.

Method for preparing (R)-N-[4-(1-amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide

Growing community of inventors

Yongin-si, South Korea

Jihae Lee